Revance Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Revance Therapeutics's past years’ income statements indicate that its last revenue has increased compared to the previous period by 77% to $234,040,000. The net income raised on -$323,986,000 and profit margin reached -138%. Total operating expenses were $398,654,000.
Profit Margin
| 2014 | 383K | -62.91M | -16427.42% |
|---|---|---|---|
| 2015 | 300K | -73.47M | -24492% |
| 2016 | 300K | -89.27M | -29756.67% |
| 2017 | 262K | -120.58M | -46025.57% |
| 2018 | 3.72M | -142.56M | -3823.22% |
| 2019 | 413K | -156.21M | -37824.94% |
| 2020 | 15.32M | -282.08M | -1840.71% |
| 2021 | 77.79M | -286.82M | -368.68% |
| 2022 | 132.56M | -356.42M | -268.87% |
| 2023 | 234.04M | -323.98M | -138.43% |
RVNC Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 234.04M | 132.56M | 77.79M | 15.32M | 413K | 3.72M | 262K | 300K | 300K | 383K |
Cost of revenue | 152.16M | 51.66M | 23.41M | 4.76M | 102.86M | 0 | 0 | 0 | 1.99M | 0 |
Gross profit | 81.87M | 80.89M | 54.38M | 10.55M | -102.44M | 3.72M | 262K | 300K | -1.69M | 383K |
Operating exp. | ||||||||||
Research and development | 79.41M | 101.28M | 116.25M | 125.79M | 102.86M | 92.5M | 80.36M | 50.38M | 47.52M | 33.39M |
Selling and marketing | 253.42M | 183.10M | 166.42M | 2.10M | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 398.65M | 353.06M | 329.06M | 283.71M | 164.87M | 146.36M | 117.75M | 79.45M | 72.61M | 52.43M |
Operating income | -316.77M | -272.16M | -274.67M | -273.16M | -164.45M | -142.63M | -120.42M | -88.21M | -72.31M | -52.05M |
Other income (expenses), net | -6.90M | -83.55M | -6.63M | -11.54M | 5.03M | -913K | -163K | -10.20M | -1.15M | -10.86M |
Income before tax | -323.68M | -355.72M | -281.31M | -284.70M | -159.42M | -139.56M | -120.58M | -89.27M | -73.47M | -62.91M |
Income tax expense | 300K | 700K | 5.51M | -2.62M | -3.21M | 3M | -1.53M | -898K | -1.13M | 8.38M |
Net income | -323.98M | -356.42M | -286.82M | -282.08M | -156.21M | -142.56M | -120.58M | -89.27M | -73.47M | -62.91M |
Earnings per share | ||||||||||
Basic EPS | -3.83 | -4.9 | -4.25 | -4.86 | -3.59 | -3.94 | -4.01 | -3.18 | -3.02 | -3.24 |
Diluted EPS | -3.83 | -4.9 | -4.25 | -4.86 | -3.59 | -3.94 | -4.01 | -3.18 | -3.02 | -3.24 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |